Migraine and Use of Progestin-Only Contraception

  • Gabriele S. Merki-FeldEmail author
Part of the Headache book series (HEAD)


Progestin-only contraception (POC) is not associated with an increased risk for cardiovascular events. In contrast to combined hormonal contraceptives, POC does not increase frequency of migraine attacks and does not initiate migraine. The continuous use of this contraceptive might contribute to the good tolerability in migraineurs. Only for the progestin-only pill with desogestrel 75 μg has it been demonstrated in several studies that it exerts significant reduction in migraine days and migraine intensity. This observation was made for migraine with and without aura. The LNG_IUS 20 is not well tolerated by many migraineurs, potentially as a result of highly fluctuating estrogen levels caused from ovarian cysts.


Migraine with aura Migraine without aura Desogestrel Levonorgestrel Contraception Progestin Intrauterine device Pill Etonogestrel implant 


  1. 1.
    Cutler SM, Cekic M, Miller DM, Wali B, VanLandingham JW, Stein DG. Progesterone improves acute recovery after traumatic brain injury in the aged rat. J Neurotrauma. 2007;24(9):1475–86.CrossRefGoogle Scholar
  2. 2.
    Wright DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC, et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med. 2007;49(4):391–402. e1-2.CrossRefGoogle Scholar
  3. 3.
    Hussain R, El-Etr M, Gaci O, Rakotomamonjy J, Macklin WB, Kumar N, et al. Progesterone and Nestorone facilitate axon remyelination: a role for progesterone receptors. Endocrinology. 2011;152(10):3820–31.CrossRefGoogle Scholar
  4. 4.
    Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care. 2008;12(2):R61.CrossRefGoogle Scholar
  5. 5.
    Schumacher M, Mattern C, Ghoumari A, Oudinet JP, Liere P, Labombarda F, et al. Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors. Prog Neurobiol. 2014;113:6.CrossRefGoogle Scholar
  6. 6.
    Chauvel V, Schoenen J, Multon S. Influence of ovarian hormones on cortical spreading depression and its suppression by L-kynurenine in rat. PLoS One. 2013;8(12):e82279.CrossRefGoogle Scholar
  7. 7.
    Prange-Kiel J, Rune GM, Zwirner M, Wallwiener D, Kiesel L. Regulation of estrogen receptor alpha and progesterone receptor (isoform A and B) expression in cultured human endometrial cells. Exp Clin Endocrinol Diabetes. 2001;109(4):231–7.CrossRefGoogle Scholar
  8. 8.
    Aguirre C, Jayaraman A, Pike C, Baudry M. Progesterone inhibits estrogen-mediated neuroprotection against excitotoxicity by down-regulating estrogen receptor-beta. J Neurochem. 2010;115(5):1277–87.CrossRefGoogle Scholar
  9. 9.
    Jayaraman A, Pike CJ. Progesterone attenuates oestrogen neuroprotection via downregulation of oestrogen receptor expression in cultured neurones. J Neuroendocrinol. 2009;21(1):77–81.CrossRefGoogle Scholar
  10. 10.
    Joshi G, Pradhan S, Mittal B. Role of the oestrogen receptor (ESR1 PvuII and ESR1 325 C->G) and progesterone receptor (PROGINS) polymorphisms in genetic susceptibility to migraine in a North Indian population. Cephalalgia. 2010;30(3):311–20.CrossRefGoogle Scholar
  11. 11.
    Buse DC, Reed ML, Fanning KM, Kurth T, Lipton RB. Cardiovascular events, conditions, and procedures among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2017;57(1):31–44.CrossRefGoogle Scholar
  12. 12.
    Roos-Hesselink JW, Cornette J, Sliwa K, Pieper PG, Veldtman GR, Johnson MR. Contraception and cardiovascular disease. Eur Heart J. 2015;36(27):1728–34. 34a-34b.CrossRefGoogle Scholar
  13. 13.
    Merki-Feld GS, Imthurn B, Langner R, Sandor PS, Gantenbein AR. Headache frequency and intensity in female migraineurs using desogestrel-only contraception: a retrospective pilot diary study. Cephalalgia. 2013;33(5):340–6.CrossRefGoogle Scholar
  14. 14.
    Merki-Feld GS, Imthurn B, Langner R, Seifert B, Gantenbein AR. Positive effects of the progestin desogestrel 75 mug on migraine frequency and use of acute medication are sustained over a treatment period of 180 days. J Headache Pain. 2015;16:522.CrossRefGoogle Scholar
  15. 15.
    Morotti M, Remorgida V, Venturini PL, Ferrero S. Progestin-only contraception compared with extended combined oral contraceptive in women with migraine without aura: a retrospective pilot study. Eur J Obstet Gynecol Reprod Biol. 2014;183:178–82.CrossRefGoogle Scholar
  16. 16.
    Nappi RE, Sances G, Allais G, Terreno E, Benedetto C, Vaccaro V, et al. Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study. Contraception. 2011;83(3):223–8.CrossRefGoogle Scholar
  17. 17.
    Nappi RE, Merki-Feld GS, Terreno E, Pellegrinelli A, Viana M. Hormonal contraception in women with migraine: is progestogen-only contraception a better choice? J Headache Pain. 2013;14:66.CrossRefGoogle Scholar
  18. 18.
    Warhurst S, Rofe CJ, Brew BJ, Bateson D, McGeechan K, Merki-Feld GS, et al. Effectiveness of the progestin-only pill for migraine treatment in women: a systematic review and meta-analysis. Cephalalgia. 2018;38:754.CrossRefGoogle Scholar
  19. 19.
    Merki-Feld GS, Imthurn B, Seifert B, Merki LL, Agosti R, Gantenbein AR. Desogestrel-only contraception may reduce headache frequency and improve quality of life in women suffering from migraine. Eur J Contracept Reprod Health Care. 2013;18(5):394–400.CrossRefGoogle Scholar
  20. 20.
    Cutrer FM, Moskowitz MA. Wolff Award 1996. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache. 1996;36(10):579–85.CrossRefGoogle Scholar
  21. 21.
    Multon S, Pardutz A, Mosen J, Hua MT, Defays C, Honda S, et al. Lack of estrogen increases pain in the trigeminal formalin model: a behavioural and immunocytochemical study of transgenic ArKO mice. Pain. 2005;114(1-2):257–65.CrossRefGoogle Scholar
  22. 22.
    Bolay H, Berman NE, Akcali D. Sex-related differences in animal models of migraine headache. Headache. 2011;51(6):891–904.CrossRefGoogle Scholar
  23. 23.
    Liu A, Margaill I, Zhang S, Labombarda F, Coqueran B, Delespierre B, et al. Progesterone receptors: a key for neuroprotection in experimental stroke. Endocrinology. 2012;153(8):3747–57.CrossRefGoogle Scholar
  24. 24.
    Kokate TG, Svensson BE, Rogawski MA. Anticonvulsant activity of neurosteroids: correlation with gamma-aminobutyric acid-evoked chloride current potentiation. J Pharmacol Exp Ther. 1994;270(3):1223–9.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department for Reproductive EndocrinologyUniversity Hospital ZürichZürichSwitzerland

Personalised recommendations